EP1863433A1 - Zusammensetzungen und verfahren zur erhöhung des stoffwechsels, der wärmeerzeugung und/oder der muskelbildung - Google Patents

Zusammensetzungen und verfahren zur erhöhung des stoffwechsels, der wärmeerzeugung und/oder der muskelbildung

Info

Publication number
EP1863433A1
EP1863433A1 EP06741359A EP06741359A EP1863433A1 EP 1863433 A1 EP1863433 A1 EP 1863433A1 EP 06741359 A EP06741359 A EP 06741359A EP 06741359 A EP06741359 A EP 06741359A EP 1863433 A1 EP1863433 A1 EP 1863433A1
Authority
EP
European Patent Office
Prior art keywords
increasing
extract
subject
composition according
thermogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06741359A
Other languages
English (en)
French (fr)
Other versions
EP1863433A4 (de
Inventor
Marvin A. Heuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIPPED FORMULATIONS LTD.
Original Assignee
Ripped Formulations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ripped Formulations Ltd filed Critical Ripped Formulations Ltd
Publication of EP1863433A1 publication Critical patent/EP1863433A1/de
Publication of EP1863433A4 publication Critical patent/EP1863433A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Definitions

  • the present invention relates to compositions and methods for increasing a person's natural metabolic rate, increasing thermogenesis or decreasing water retention.
  • the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder; and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum.
  • the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate.
  • the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention.
  • the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
  • the present invention provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition.
  • Certain embodiments of the present invention include diet supplements.
  • the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
  • the present invention provides compositions and methods that decrease water retention in subjects.
  • the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
  • a composition and related methods comprise: a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
  • the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate.
  • the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
  • the diet supplement may be consumed in any form.
  • the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a caplet, or as a dietary gel.
  • the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
  • a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects.
  • the compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition.
  • the dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject.
  • the compositions according to the present invention are administered to the subject on a daily basis.
  • the compositions according to the present invention are administered to the subject three times daily.
  • the present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject.
  • the methods of the present invention include administering a composition to a subject.
  • methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided.
  • the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
  • the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention.
  • the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
  • compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
  • the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
  • compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • the methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition.
  • the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete.
  • the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
  • the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g
  • the example composition may be ingested 30 to 60 minutes prior to eating a meal.
  • the example composition can also be consumed prior exercise to increase and athlete's training intensity.
  • the example composition may be ingested 30 to 60 minutes prior to eating a meal.
  • the example composition can also be consumed prior exercise to increase and athlete's training intensity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP06741359A 2005-03-18 2006-03-20 Zusammensetzungen und verfahren zur erhöhung des stoffwechsels, der wärmeerzeugung und/oder der muskelbildung Withdrawn EP1863433A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66339605P 2005-03-18 2005-03-18
PCT/CA2006/000415 WO2006096996A1 (en) 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition

Publications (2)

Publication Number Publication Date
EP1863433A1 true EP1863433A1 (de) 2007-12-12
EP1863433A4 EP1863433A4 (de) 2009-09-09

Family

ID=36991257

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06741359A Withdrawn EP1863433A4 (de) 2005-03-18 2006-03-20 Zusammensetzungen und verfahren zur erhöhung des stoffwechsels, der wärmeerzeugung und/oder der muskelbildung

Country Status (5)

Country Link
EP (1) EP1863433A4 (de)
AU (1) AU2006225005A1 (de)
CA (1) CA2600301A1 (de)
WO (1) WO2006096996A1 (de)
ZA (1) ZA200708361B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904070A4 (de) * 2005-07-07 2009-09-02 H3 Formulations Ltd Nahrungsergänzung zur verbesserung der skelettmuskelmasse, verringerung des muskelproteinabbaus, downregulierung von muskel-katabolismuspfaden und verringerung des katabolismus von muskelzellen
US20210077517A1 (en) * 2008-06-13 2021-03-18 International IP Holdings Edible Energy Composition
US10881661B2 (en) * 2008-06-13 2021-01-05 International Ip Holdings Llc Edible energy composition
FR2938735B1 (fr) * 2008-11-21 2012-12-28 Holymark Composition amaigrissante, en particulier pour sportifs, administrable par voie orale et complement alimentaire integrant une telle composition.
EP2440206B1 (de) * 2009-06-11 2018-07-18 DSM IP Assets B.V. Trigonellin als Muskelstimulans
ES2386858B1 (es) * 2011-02-07 2013-03-22 Eduardo Antonio Gómez De Diego Composición adelgazante natural.
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA3050823C (en) 2018-03-20 2021-02-23 Mark TARNOPOLSKY Weight management composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Pro-Cuts-Ephedra Free" SCIFITNESS, [Online] 19 November 2004 (2004-11-19), XP002535824 Retrieved from the Internet: URL:http://www.scifitauthentic.com/productdetail.asp?navid=2&pid=46> [retrieved on 2009-07-07] *
KARAYEV ET AL: "Preclinical study of picamilon and benzaflavine" PHARMACOLOGICAL RESEARCH, vol. 31, 1 January 1995 (1995-01-01), page 262, XP022359432 ACADEMIC PRESS, LONDON, GB ISSN: 1043-6618 *
See also references of WO2006096996A1 *

Also Published As

Publication number Publication date
EP1863433A4 (de) 2009-09-09
ZA200708361B (en) 2008-10-29
AU2006225005A1 (en) 2006-09-21
WO2006096996A1 (en) 2006-09-21
CA2600301A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
EP1863433A1 (de) Zusammensetzungen und verfahren zur erhöhung des stoffwechsels, der wärmeerzeugung und/oder der muskelbildung
US20060210653A1 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
US7989009B2 (en) Composition and method for promoting weight loss
US20050249827A1 (en) Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
EP3590521B1 (de) Synergistische nahrungsergänzungszusammensetzungen zur verbesserung der physischen leistungs- und energiestufen
US9220741B2 (en) Weight loss formulation
US7943183B2 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
AU2007222860A1 (en) Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
Cherniack Potential applications for alternative medicine to treat obesity in an aging population
WO2018112475A1 (en) Energy compositions and methods
US20040097429A1 (en) Method for the reduction of the mammalian appetite
US20080279967A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid
US20130280367A1 (en) Method and Composition for Increasing Energy and Focus
CA2751218C (en) Weight loss formulation
JP2005126379A (ja) 細胞内脂質沈着の排出を刺激するためのビタミン類、ミネラル類および微量元素の新規な相乗作用性組成物
US20050276870A1 (en) Food supplement formulation
EP2582352A2 (de) Lippenkosmetikformulierungen
PT103650B (pt) Composições de extractos vegetais
KR20050038766A (ko) 세포내 지질 부착물 제거를 자극하는 비타민, 미네랄 및미량원소로 이루어진 새로운 상승작용성 조성물
CA2588491A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid profile

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101ALI20080213BHEP

Ipc: A61K 36/82 20060101AFI20080213BHEP

Ipc: A61K 36/38 20060101ALI20080213BHEP

Ipc: A61K 31/4415 20060101ALI20080213BHEP

Ipc: A61K 36/288 20060101ALI20080213BHEP

Ipc: A61K 36/77 20060101ALI20080213BHEP

Ipc: A61K 31/51 20060101ALI20080213BHEP

Ipc: A61K 36/14 20060101ALI20080213BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RIPPED FORMULATIONS LTD.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HEUER, MARVIN, A.

A4 Supplementary search report drawn up and despatched

Effective date: 20090811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001